| |
Cell and gene therapies have revealed great promise for the treatment of rare diseases. But development of these advanced therapeutics is complex - requiring careful attention to study design and patient safety.
Read our guide to understand the current landscape of cell and gene therapy (CGT) and explore expert insights on the key challenges and questions to address when designing trials in rare diseases. Premier Research. Built for Biotech℠ 
|
|
Today’s Big NewsApr 12, 2024 |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
| By Gabrielle Masson In the same week that Genentech confirmed it's cutting 3% of its staff, the Roche subsidiary has terminated a cell therapy partnership with Adaptimmune Therapeutics worth up to $3 billion. |
|
|
|
By James Waldron Novartis may have emerged victorious from a bidding war for MorphoSys, but a peek into the deal negotiations reveals that the Swiss pharma would have been happier if it could have walked away with one specific asset. |
By Nick Paul Taylor Enlivex Therapeutics had a message Friday for investors who halved its share price: You’re misreading our data. The cell therapy developer blamed imbalances between cohorts for the mixed results—and contended the effect on a small subgroup of sepsis patients suggests the candidate has a future. |
By Max Bayer Portage Biotech is in a financial bind and is not precluding a possible closure if it can't find another option. The company is halting enrollment in a phase 1 study testing two adenosine receptor agonists as the strategic hunt proceeds. |
By Max Bayer,Gabrielle Masson At one of the most consequential times for the biotech industry, the head lobbyist at the top trade organization is gone. Nick Shipley, BIO’s chief advocacy officer, left the organization last week, a spokesperson confirmed. |
By Ayla Ellison,Gabrielle Masson,Max Bayer Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. |
By Conor Hale The DNA sequencing giant still has the freedom to choose between selling the cancer blood test developer to another party outright or supporting its journey to the public markets as an independent spinout. |
By Zoey Becker The regulators began investigating meds in the GLP-1 drug class for a potential association in July after two reported cases of suicidal thoughts and one of self-harm. |
By Paige Minemyer The Centers for Medicare & Medicaid Services is expecting outlays on Alzheimer's drug Leqembi that far outpace the drugmaker's estimates next year. |
By Zoey Becker FDA Commissioner Robert Califf, M.D., told lawmakers that the agency, as the "referee," needs to be given more authority in order to preemptively halt drug shortages. The Oversight Committee hearing touched on a range of other issues, too. |
By Angus Liu Geopolitical tensions are casting uncertainties over cross-border biotech deals. Johnson & Johnson and Legend Biotech's Carvykti, plus AstraZeneca and Daiichi Sankyo's Enhertu, secured new FDA approvals. Fujifilm is making a big investment in its facility in North Carolina. And more. |
Fierce podcasts Don’t miss an episode |
| Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. |
|
|---|
|
|
|
Tuesday, April 30, 2024 | 2pm ET / 11am PT Liquid biopsies have shown tremendous progress for the early detection of cancer and for treatment monitoring, but still have limitations. The inclusion of protein glycosylation can help. Join usto learn more about the latest solutions for leveraging AI and machine learning to accelerate data processing, overcome current barriers, and provide crucial information. Register now. 
|
|
eBook Unlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
